Company Description
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally.
The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.
The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors.
The company was incorporated in 1992 and is headquartered in Winter Springs, Florida.
| Country | United States |
| Founded | 1992 |
| IPO Date | Jul 16, 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 160 |
| CEO | Roger Susi |
Contact Details
Address: 1025 Willa Springs Drive Winter Springs, Florida 32708 United States | |
| Phone | 407 677 8022 |
| Website | iradimed.com |
Stock Details
| Ticker Symbol | IRMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001325618 |
| CUSIP Number | 46266A109 |
| ISIN Number | US46266A1097 |
| Employer ID | 73-1408526 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Roger E. Susi | Founder, Chairman, Chief Executive Officer and President |
| John F. Glenn | Chief Financial Officer and Corporate Secretary |
| Randy Waddell | Vice President of Worldwide Sales and Marketing |
| Chris Williamson | Executive Vice President of Continuous Improvement and Information Technology |
| Jeff Chiprin | Chief Commercial Officer |
| Matt Garner | Controller |
| Lynn Neuhardt | Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | SCHEDULE 13G/A | Filing |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |